MDPI Pharmaceutics · Mar 2026
Peer-reviewed publication reporting preclinical results for human-milk-inspired antimicrobial peptides against BV-associated pathogens, including selectivity and safety findings that support Matrubials’ lead program.
Developing milk-inspired therapeutics for infectious diseases
Company research
Public company, workplace, funding, and market signals
Overview
Matrubials is a Davis, California–based, UC Davis spin-off drug-discovery company developing milk-inspired antimicrobial therapeutics for infectious diseases, with an initial focus on bacterial vaginosis and other women’s health / skin-health applications.
Primary product
Milk-inspired antimicrobial peptide therapeutics for bacterial vaginosis and infectious diseases
Founded
2018
Headquarters
Davis, California, United States
Team size
1-10
Industry
Biotechnology Research
Sub-industry
Anti-infectives / therapeutics drug discovery
Offices
Davis, California, United States
Business model
drug discovery
therapeutics development
grant-funded R&D
Funding
Stage
seed-stage / early-stage
Latest round
Grant (SEGA Health & Life Science Pitch Showcase / Accelerate CA) · Dec 2025
Latest amount
$50K
People & investors
Leadership
Co-founder and Chief Executive Officer
Co-founder
Co-founder; Professor / Director, Foods For Health Institute
Co-founder; Distinguished Professor
Work & culture
Public materials describe an early-stage, collaborative, entrepreneurial team and emphasize inclusion, diversity, and equity; no formal benefits package is publicly listed.
Product & market
Differentiators
- —Milk-inspired human / mammalian peptide therapeutics
- —AI-enabled discovery and validation platform
- —Selective activity aimed at sparing beneficial vaginal lactobacilli
- —Initial focus on topical BV treatment
- —UC Davis spin-off with deep academic founder expertise
Technology
AI-enabled candidate expansion and validation platform
milk-derived peptide discovery
antimicrobial peptide therapeutics
in vitro infection assays
mass spectrometry-based bioactive molecule discovery
Customers
women of reproductive age with bacterial vaginosis
patients with drug-resistant bacterial infections
future users of topical skin-health therapeutics
Competitors
Spero Therapeutics
BioNTech
Evofem
Scale & contact
Estimated revenue
about $0.5M annually (third-party estimate)
Estimated monthly visits
598
Latest news
MedStart · Dec 2025
Reports Matrubials won a $50,000 non-dilutive grant via the State of California’s Accelerate CA program and summarizes the company’s BV-focused milk-inspired therapeutic approach.
San Francisco Biotechnology Network · Dec 2025
Reports Matrubials plans a consumer skin-care launch alongside its drug candidate, showing a dual-track commercial strategy.
Comstock’s magazine
Profiles the company’s UC Davis spin-out origins, funding history, and antibacterial-peptide strategy for bacterial vaginosis.
Jobs and careers at Matrubials
0 jobs at Matrubials
No open positions
Check back later for new openings